Validity Diagnostics to showcase second-generation urine validity reagents in Chicago

Validity Diagnostics plans to highlight its second-generation urine specimen validity reagents at the SOFT-TIAFT 2026 Joint Meeting in Chicago on Sept. 19-24, 2026. The company says its True Essentials Panel is designed to help labs and employers detect synthetic and adulterated urine as drug-test subversion grows more sophisticated.

Why it matters: - Synthetic and adulterated urine can undermine workplace, court and government drug testing programs. - Validity Diagnostics says its second-generation reagents are designed to help laboratories detect those samples before they compromise compliance or safety. - The issue affects Fortune 500 employers, federal and state government employers, drug courts, probation offices and drug testing laboratories.

What happened: - Validity Diagnostics will showcase its second-generation urine specimen validity reagents at the SOFT-TIAFT 2026 Joint Meeting in Chicago, Illinois, on Sept. 19-24, 2026. - The company will present the True Essentials Panel, which includes Oxidant History, True Urine LD and True Urine SD reagents. - Validity Diagnostics is based in Branford, Florida.

The details: - The True Essentials Panel is positioned as a tool for detecting synthetic and/or adulterated urine in drug testing programs. - Validity Diagnostics says the panel gives drug testing laboratories dependable, science-backed tools to identify urine sample subversion. - Donna Suggs, CEO of Validity Diagnostics, said workplace urine drug testing depends on the integrity of the urine sample. - Suggs also said urine sample subversion is becoming more sophisticated. - Garet Rembert, co-founder and vice president of sales, said synthetic urine is a billion-dollar industry built to defeat drug tests. - Rembert said peer-reviewed research from the U.S. military and RTI International confirmed that standard validity testing cannot detect synthetic urine. - Rembert said VDx patented technology has identified synthetic urine in multiple independent studies when laboratories use the right tools.

Between the lines: - The announcement frames synthetic urine as a growing technical arms race, not just a compliance problem. - Validity Diagnostics is leaning on outside research to argue that older validity tests are no longer enough. - The company is also trying to position its products as a response to evolving synthetic urine products that may evade conventional screening.

What's next: - Validity Diagnostics will use the Chicago meeting to market the True Essentials Panel to labs, employers and testing administrators. - The company is expected to continue citing 2025 research from Franke et al. at Jena University Hospital in Germany and RTI International in Research Triangle Park, North Carolina. - Those studies found True Urine LD and True Urine SD outperformed conventional validity tests when identifying synthetic urine.

The bottom line: - Validity Diagnostics is betting that drug-testing customers will pay for more advanced validity tools as synthetic urine becomes harder to catch.